[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100526960":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":22,"centralContacts":28,"locations":35,"responsibleParty":49,"collaborators":51,"id":60,"slug":10,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":10,"studyType":73,"phases":10,"briefSummary":74,"conditions":75,"keywords":78,"overallStatus":81,"whyStopped":10,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"First Affiliated Hospital Xi'an Jiaotong University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental group",null,"Adequate and regular anticoagulant therapy. Anticoagulation therapy is determined based on the patient's CHADS₂ or CHA₂DS₂-VASc score. Anticoagulant medications include vitamin K antagonists, novel oral anticoagulants (NOACs), and aspirin.",[13],"Other: Observational; No Interventions were given.",{"label":15,"type":10,"description":16,"interventionNames":17},"Control group","Patients who have not received regular or continuous anticoagulation therapy due to poor compliance or other reasons.",[13],[19],{"type":6,"name":20,"description":20,"armGroupLabels":21,"otherNames":10},"Observational; No Interventions were given.",[15,9],[23,26],{"name":24,"affiliation":5,"role":25},"Guoliang Li","PRINCIPAL_INVESTIGATOR",{"name":27,"affiliation":5,"role":25},"Chaofeng Sun",[29,33],{"name":24,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","+8613759982523","liguoliang_med@163.com",{"name":27,"role":30,"phone":10,"phoneExt":10,"email":34},"cfsun1@mail.xjtu.edu.cn",[36],{"facility":37,"status":10,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":10},"First Affiliated Hospital of Xian Jiantong University","Xi'an","Shaanxi","710061","China","CN",{"type":44,"coordinates":45},"Point",[46,47],108.92861,34.25833,{"lat":47,"lon":46},{"type":50,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[52,54,56,58],{"name":53,"class":6},"521 Hospital of NORINCO Group",{"name":55,"class":6},"Shaanxi Provincial People's Hospital",{"name":57,"class":6},"Xiangyang Central Hospital",{"name":59,"class":6},"Henan Provincial People's Hospital","100526960",false,"NCT06141538","Response of Intracardiac Thrombus to Anticoagulants in Patients With Non-valvular Atrial Fibrillation (LYSIS)","Response of Intracardiac Thrombus to Anticoagulants in Patients With Non-valvular Atrial Fibrillation (LYSIS): an Investigator-initiated, National, Multicenter, Retrospective-prospective, Observational Cohort Study","LYSIS","Inclusion Criteria:\n\n* Age ≥18 years old, age ≤80 years old\n* Patients with atrial fibrillation detected by routine surface 12-lead electrocardiography or Holter\n* Transesophageal echocardiography confirmed the presence of cardiac thrombus, and the patient had not received any anticoagulant therapy\n\nExclusion Criteria:\n\n* Echocardiography confirmed valvular heart disease\n* Contraindications to anticoagulants\n* Patients with the previous history of hemorrhagic stroke\n* Low platelet count or functional platelet defects\n* Congenital or acquired coagulation or bleeding disorders\n* Abnormal liver function (liver enzymes \\>2 times the upper limit)\n* Renal failure (endogenous creatinine clearance \\\u003C30ml\u002Fmin)\n* Surgery was planned within the intended study time or had been operated within 30 days before the study\n* Other comorbidities that can cause bleeding, such as tumors\n* Patients with autoimmune diseases or immunodeficiency, or patients who are currently using immunosuppressants and immunomodulators\n* Patients are currently participating in other clinical studies","ALL","18 Years","80 Years",{"count":71,"type":72},500,"ESTIMATED","OBSERVATIONAL","This study aims to analyze changes in the immune status, metabolic status, and host microbiome community structure in non-valvular atrial fibrillation patients with intracardiac thrombus. Additionally, the study aims to analyze factors that influence the responsiveness and occurrence of adverse events related to anticoagulant therapy.",[76,77],"Atrial Fibrillation","Intracardiac Thrombus",[76,77,79,80],"Anticoagulation Therapy","Major adverse cardiovascular and cerebrovascular events","NOT_YET_RECRUITING","2024-04-02",{"date":84,"type":85},"2024-04-04","ACTUAL",{"date":87,"type":72},"2024-12-31",{"date":89,"type":72},"2030-12-31",{"name":5,"class":6},1]